PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q92967

Noboru YAMAZAKI, et al.

Appln. No.: 10/566,566 Group Art Unit: 1612

Confirmation No.: 6156 Examiner: Gollamudi S. KISHORE

Filed: August 21, 2006

For: TARGETING AND INTESTINAL-ABSORPTION CONTROLLED LIPOSOME HAVING SUGAR CHAIN AND THERAPEUTIC DRUG FOR CANCER AND DIAGNOSTIC DRUG CONTAINING THE LIPOSOME

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

That no item of information contained in the Information Disclosure Statement filed concurrently herewith was cited in any communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making a STATEMENT UNDER 37 C.F.R. § 1.97(e) Attorney Docket No.: Q92967

U.S. Application No.: 10/566,566

reasonable inquiry, no item of information contained in the information disclosure statement was

known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the

filing of said Information Disclosure Statement.

Respectfully submitted,

/Renita S. Rathinam/

Renita S. Rathinam Registration No. 53,502

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: July 21, 2010